IGA

Alcor Announces the New Release of AccessFlow, an Enterprise Identity and Access Management Solution

Retrieved on: 
Tuesday, March 19, 2024
Cloud, CIAM, RBAC, Organization, Active Directory, Access management, GUI, SAN, Role-based access control, Policy, Access control, PST, IAM, AWS, Certification, Google Workspace, Identity management, App Store (iOS/iPadOS), Segregation, Security, Access, Administration, SOD, IGA, Asset management

It is an automated, self-service enterprise identity and access management (IAM) product, natively built and certified on the ServiceNow® platform.

Key Points: 
  • It is an automated, self-service enterprise identity and access management (IAM) product, natively built and certified on the ServiceNow® platform.
  • Alcor's IAM product reinvents the Enterprise Identity and Access Management for modern businesses.
  • Combining Access Management (AM) and Identity Governance and Administration (IGA) capabilities seamlessly, it provides an all-in-one solution for modern businesses.
  • The latest AccessFlow release marks a significant milestone in optimizing enterprise access management and identity governance for modern businesses seeking cloud-native and self-service solutions.

More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study

Retrieved on: 
Sunday, March 10, 2024
Diagnosis, Pigment, LLY, Weill Cornell Medicine, Atopic dermatitis, Health equity, Alaska Natives, Patient, Education, PDCA, Advocate, Diversity, Adherence, Immunology, Research, American Academy, Human, Weill Cornell Medical Center, Dermatitis, African, Skin, Safety, Lilly, Eli Lilly and Company, AAD, Health, IGA, Almirall, Pharmaceutical industry

In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief.

Key Points: 
  • In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief.
  • These late-breaking results from a Phase 3 study are being presented today at the American Academy of Dermatology (AAD) Annual Meeting.
  • "People with skin of color are disproportionately affected by atopic dermatitis, often experiencing more severe symptoms, a delay in diagnosis and a lengthier timeframe to find appropriate treatment.
  • "With these initial results, Lilly is taking a step toward investigating the needs of people with skin of color affected by atopic dermatitis."

Latest data of InnoCare's ICP-332 for the Treatment of Atopic Dermatitis Presented at LBA Session of 2024 AAD

Retrieved on: 
Wednesday, March 13, 2024
High, Safety, HKEX, AAD, IGA, Patient, TYK2, Trial of the century, NRS, American Academy, Pharmaceutical industry

75 eligible AD patients were randomized into three groups: once daily oral ICP-332 80 mg, once daily oral 120 mg, and placebo respectively.

Key Points: 
  • 75 eligible AD patients were randomized into three groups: once daily oral ICP-332 80 mg, once daily oral 120 mg, and placebo respectively.
  • ICP-332 demonstrated a rapid response, with the NRS score from baseline in the two treatment groups showing statistically significant improvement on day 2.
  • With the improvement of pruritus, the quality of life of subjects in the two treatment groups was significantly elevated.
  • The 2024 AAD Annual Meeting is held from March 8 to 12 in San Diego, California, USA.

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 11, 2024
Therapy, SAN, Ulcerative colitis, Week, CDAI, B cell, Atopic dermatitis, BTLA, Q2, PD-1, Inflammation, Annual general meeting, AAD, UC, Idealized cognitive model, Rheumatoid arthritis, IGA, Patient, BDCA2, IND

“We will have a number of important events in 2024 including the top-line data readout of ANB032's Phase 2b trial in atopic dermatitis by year end,” adds Faga. “We also plan to move our third and fourth ICMs -- ANB033, our anti-CD122 antagonist, and ANB101 -- into the clinic this year, with IND filings planned for Q2 and H2, respectively.”

Key Points: 
  • “Enrollment is ongoing in three global Phase 2 trials for ANB032, our BTLA agonist, in atopic dermatitis and rosnilimab, our PD-1 agonist, in rheumatoid arthritis and ulcerative colitis.
  • The decrease relates primarily to cash used for operating activities and the $50 million stock repurchase program.
  • The change is due primarily to increased royalties recognized for sales of Jemperli offset by one development milestone achieved for cobolimab in 2022.
  • Acquired in-process research and development of $7.3 million for the three and twelve months ended December 31, 2023 related to the exclusive licensing agreement with Centessa Pharmaceuticals.

ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

Retrieved on: 
Monday, March 11, 2024
Allergy, SAN, Conjunctivitis, Inflammation, EASI, Skin, Data, Cytokine, IGA, Patient, Disease, Dupilumab, ASLN, Pharmaceutical industry

In conjunction with this, independent reviewer confirmation of baseline EASI scores has also been implemented.

Key Points: 
  • In conjunction with this, independent reviewer confirmation of baseline EASI scores has also been implemented.
  • Of the 9 patients who previously had an inadequate response to dupilumab, 5 patients (56%) achieved EASI-90 and 5 patients (56%) a vIGA score of 0 or 1.
  • Additional data from head-to-head studies between eblasakimab and dupilumab in skin biopsies from AD patients confirmed the differentiated effects of targeting IL-13R versus IL-4R5.
  • In this study, eblasakimab reduced localized secretion of pro-inflammatory Type 2 cytokines by the skin tissue more efficiently than dupilumab, suggesting eblasakimab could have the potential to be effective in AD patients that do not achieve an adequate response to dupilumab.

Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis

Retrieved on: 
Monday, March 11, 2024
Eosinophil, Fever, Week, Headache, OX40L, Conjunctivitis, Scleroderma, Teaching hospital, Atopic dermatitis, Upper respiratory tract infection, Part, Asthma, TARC, Conference, AAD, Safety, Biomarker, Part Two, Hidradenitis suppurativa, IGA, Patient, Inflammation, Chills, Moa, Serum, American Academy, Pharmaceutical industry

The safety profile was consistent with Part 1 of the study with amlitelimab being well-tolerated and no new safety concerns identified.

Key Points: 
  • The safety profile was consistent with Part 1 of the study with amlitelimab being well-tolerated and no new safety concerns identified.
  • Overall rates of treatment-emergent adverse events (TEAEs) were 69.8% for continued amlitelimab treatment, 71.9% for the amlitelimab withdrawal-arm and 66.7% for placebo.
  • TEAEs more commonly observed included headache (11.6% amlitelimab continuation, 3.9% amlitelimab withdrawal, 6.7% placebo), upper respiratory tract infection (9.3% amlitelimab continuation, 5.5% amlitelimab withdrawal, 20% placebo).
  • Amlitelimab is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority.

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

Retrieved on: 
Saturday, March 9, 2024
The Department, SAN, Immunodeficiency, Psoriasis, Doctor of Philosophy, Waldman, STAT1, IL22, MD, Mount Sinai Health System, Dermatitis, Atopic dermatitis, Biopsy, RNA-Seq, OASL, Rosacea, Laboratory, AAD, CXCL9, FA2H, Hospital, RNA, Immunology, IGA, Patient, Gene, PI3, Seborrhoeic dermatitis, Skin condition, Observational study, Skin, Research, Gene expression, American Academy, Vaccine

“We are excited to have successfully employed noninvasive tape-stripping techniques developed from studying these diseases to study an understudied and undertreated inflammatory skin disease, seborrheic dermatitis.

Key Points: 
  • “We are excited to have successfully employed noninvasive tape-stripping techniques developed from studying these diseases to study an understudied and undertreated inflammatory skin disease, seborrheic dermatitis.
  • These findings will help establish the groundwork for greater understanding of this very common condition.”
    “The pathophysiology of seborrheic dermatitis has been poorly understood.
  • In addition, the skin barrier disruption observed in seborrheic dermatitis has unique molecular underpinnings, primarily in the tight junction of the epithelial skin cells and lipid metabolism pathways.
  • These data demonstrate that seborrheic dermatitis is an immune disease with a uniquely polarized profile distinct from atopic dermatitis and plaque psoriasis.

Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Sc

Retrieved on: 
Tuesday, March 5, 2024
Paragon, Well, SAD, PD, Injection, I&I, Waldman, Headache, Inflammation, Quality of life, Management, Atopic dermatitis, Asthma, TARC, AUC, Volunteering, Cmax, Chronic obstructive pulmonary disease, Outline of health sciences, Safety, Biomarker, Therapy, CQD, Chronic pain, Immunology, IGA, Webcast, Sleep, Patient, MPH, Half-life, Serum, Pharmaceutical industry

Based on these data, the company plans to initiate a randomized, placebo-controlled, Phase 2 clinical trial in patients with moderate-to-severe AD in the first half of 2024 ahead of schedule.

Key Points: 
  • Based on these data, the company plans to initiate a randomized, placebo-controlled, Phase 2 clinical trial in patients with moderate-to-severe AD in the first half of 2024 ahead of schedule.
  • At Apogee, we refuse to stop at good enough and are dedicated to advancing innovative solutions for patients.
  • The Phase 1 trial is a first-in-human, randomized, double-blind, placebo-controlled study designed to evaluate safety and PK of APG777 in healthy volunteers.
  • A live webcast of the call will be available on the Investor Relations page of Apogee’s website at https://investors.apogeetherapeutics.com/news-events/events .

Amethyst Beverage Ramps Up Major Events for the Spring and Summer Due to Increased Demand for Its CBD Water

Retrieved on: 
Wednesday, February 28, 2024
Humic substance, Aloe vera, Season, Fitness, HDI, Drink, Nation, IGA, CBD, Convention, Science, Taste, Water

These events will include Music festivals and specialized marketing events at Fitness and Retail locations.

Key Points: 
  • These events will include Music festivals and specialized marketing events at Fitness and Retail locations.
  • The Spring Festival season will be kicking off in April 2024 in Lake Havasu, Arizona.
  • Amethyst Beverage will be the sponsor of and exclusive water rights for each event.
  • We will also start including our specialty Fulvic Acid, Ionic Minerals and Aloe Vera in the product line as well.

Saviynt to Present the Latest Identity Security Strategies at IT Security Analyst and CISO Forum 2024 in London

Retrieved on: 
Thursday, March 7, 2024
Data Management, Security, Technology, Software, Networks, Internet, Cloud, Research, EIC, Cognizant, Growth, Barclays, NHS, Administration, Software as a service, CISO, IGA, Map, GSK plc, IDC, North River Steamboat, Risk management

Saviynt , a leading provider of cloud-native identity and governance platform solutions, is pleased to announce its participation at the 2024 IT Security Analyst and CISO Forum taking place 18th – 19th March at The Clermont Charing Cross in London.

Key Points: 
  • Saviynt , a leading provider of cloud-native identity and governance platform solutions, is pleased to announce its participation at the 2024 IT Security Analyst and CISO Forum taking place 18th – 19th March at The Clermont Charing Cross in London.
  • Jonanthan Neal, field CTO at Saviynt, will represent Saviynt at the event.
  • Neal is well versed in both enterprise business requirements, as well as the latest identity security technologies and strategies.
  • He offers his insights into how Saviynt helps CISOs protect their identity perimeters, and can discuss the benefits of converged identity as realized by many different customers’ identity security projects.